|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-12-31
|
|
pubmed:abstractText |
Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in the treatment of poor-prognosis AML in elderly patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:CairdJJ,
pubmed-author:FianchiLL,
pubmed-author:GianfaldoniGG,
pubmed-author:LeoneGG,
pubmed-author:LeoniFF,
pubmed-author:PaganiFF,
pubmed-author:RutellaSS,
pubmed-author:ScardocciAA,
pubmed-author:StortiSS,
pubmed-author:ValentineC CCC,
pubmed-author:VosoM TMT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
128-34
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17906298-Aged,
pubmed-meshheading:17906298-Aminoglycosides,
pubmed-meshheading:17906298-Antibodies, Monoclonal,
pubmed-meshheading:17906298-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17906298-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17906298-Bone Marrow Diseases,
pubmed-meshheading:17906298-Cytarabine,
pubmed-meshheading:17906298-Disease-Free Survival,
pubmed-meshheading:17906298-Female,
pubmed-meshheading:17906298-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:17906298-Humans,
pubmed-meshheading:17906298-Infection,
pubmed-meshheading:17906298-Leukemia, Myeloid, Acute,
pubmed-meshheading:17906298-Leukemia, Myelomonocytic, Acute,
pubmed-meshheading:17906298-Male,
pubmed-meshheading:17906298-Neoplasms, Second Primary,
pubmed-meshheading:17906298-Prognosis,
pubmed-meshheading:17906298-Remission Induction,
pubmed-meshheading:17906298-Risk
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
|
|
pubmed:affiliation |
Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy. luana.fianchi@rm.unicatt.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Multicenter Study
|
